← Who reports today · Health Care
How Gilead Sciences (GILD) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · reported 08/04/2026
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. · Wikipedia
More about the company
It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. Market share (US pharma & biotech): ≈4% by TTM revenue.
Key growth driver: Royalty & Contract — the fastest-growing revenue line: $176, +552% y/y. · by the Q2 2026 report
How does Gilead Sciences make money?
Gilead Sciences brought in $7.80 billion of revenue in Q2 2026, up 10.2% year over year. The largest source was HIV: $5.69 billion, or 73% of the total, followed by Liver Disease ($877M, 11%) and Oncology ($873M, 11%); other lines add the remaining 5%.
Revenue by source, Q2 2026
- HIV$5.69B · 73% · +11.9%
- Liver Disease$877M · 11% · +10.3%
- Oncology$873M · 11% · +2.8%
- Royalty & Contract$176M · 2% · +552%
- Other Products$161M · 2% · −20.3%
- Veklury$23.0M · 0.3% · −81%
Shares of $7.80B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is GILD’s next earnings date?
Thursday, October 29, 2026estimated
Gilead Sciences (GILD) has not confirmed the date yet; Oct 29, 2026 is an estimate based on the company's past reporting schedule and may move once the date is announced. Consensus EPS forecast: $2.15 (6 analysts), vs $2.47 in the same quarter last year.
What time does GILD report? Usually after market close: the last 4 results releases reached the SEC at 4:03 pm, 4:03 pm, 4:02 pm, 4:04 pm ET.
Last report: Aug 4, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Verdict: the biggest GAAP loss of this earnings season — $10.5B — is pure deal accounting: $11.2B of acquired IPR&D (Arcellx $7.0B, Tubulis $3.1B, Ouro $1.0B) and a $1.75B Immunomedics-related impairment landed in one quarter while the underlying business grew 10% ex-Veklury with HIV up 12%.
Loss quarter (mirror layout): left side shows where the money came from — revenue, other income and the net loss itself; right side shows what it covered. Q2 operating cash flow $3.6B; dividends $1.0B, buybacks $355M; cash fell to $3.2B from $10.6B YE2025 after $11.3B YTD spent on acquisitions.
Source and notation
* marks non-cash / ≈ estimated. Source: Gilead Sciences press release 8-K EX-99.1 (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Heads-up
- a net loss in Q2 2026 ($10,496 · vs +$1,960)
Most likely because on top of that, a $1,750M in-process R&D impairment on assets previously acquired from Immunomedics (after the EVOKE-03 lung-cancer study with Keytruda was discontinued); tax paradox: $242M of income tax EXPENSE on a $10,254M pretax LOSS; costs grew faster than revenue (sg&a +41% y/y, r&d +18% y/y). Based on the Q2 2026 report.
Company filings on SEC EDGAR ↗GILD earnings history: past report dates
| Aug 4, 2026 Tue | 4:03 pmafter market close | Jun 30, 2026 | $7.8B+10% y/y | −$8.45 |
| May 7, 2026 Thu | 4:03 pmafter market close | Mar 31, 2026 | $7.0B+4% y/y | $1.61+55% y/y |
| Feb 10, 2026 Tue | 4:02 pmafter market close | Dec 31, 2025 | ≈$7.9B+5% y/y | ≈$1.75+22% y/y |
| Oct 30, 2025 Thu | 4:04 pmafter market close | Sep 30, 2025 | $7.8B+3% y/y | $2.43+143% y/y |
| Aug 7, 2025 Thu | 4:26 pmafter market close | Jun 30, 2025 | $7.1B+2% y/y | $1.56+21% y/y |
| Apr 24, 2025 Thu | 4:03 pmafter market close | Mar 31, 2025 | $6.7B−0% y/y | $1.04 |
| Feb 11, 2025 Tue | 4:04 pmafter market close | Dec 31, 2024 | ≈$7.6B+6% y/y | ≈$1.43+25% y/y |
| Nov 6, 2024 Wed | 4:09 pmafter market close | Sep 30, 2024 | $7.5B+7% y/y | $1.00−42% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Gilead Sciences: 5-year financials
| 2025 | 29,443 | 10,022 | 8,510 | 9,456 | 4,003 |
| 2024 | 28,754 | 1,662 | 480 | 10,305 | 3,918 |
| 2023 | 27,116 | 7,605 | 5,665 | 7,421 | 3,809 |
| 2022 | 27,281 | 7,330 | 4,592 | 8,344 | 3,709 |
| 2021 | 27,305 | 9,918 | 6,225 | 10,805 | 3,605 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
2/2good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Feb 2026Per the cover of its 2025 10-K, one class is registered — GILD common stock; the legal proceedings section contains no shareholder suits or SEC cases (only antitrust and product cases). sec.gov ↗
- Dec 2025Declared dividend per share has risen every year: $2.72 (2020), $2.92 (2022), $3.16 (2025) (XBRL 10-K). data.sec.gov ↗
- Dec 2025Diluted share count fell 0.6% over 2020→2025; SBC is 3.0% of revenue; buybacks of $1.9B in 2025 (XBRL 10-K). data.sec.gov ↗
Scoring: 2.0, no deductions = 2.0
- Share classes
- Single class of common stock (10-K cover).
- Dilution
- Diluted share count 2020→2025 −0.6%; SBC 3.0% of revenue; buybacks of $0.5–1.9B a year.
- Disclosure
- 10-Ks and 10-Qs filed on time, audited US GAAP financials; no deduction.
- Dividends
- Dividend paid since 2015 and raised every year: $2.72 (2020) → $3.16 (2025); no cuts.
- Lawsuits & regulators
- The 10-K lists antitrust (HIV drugs) and product suits — industry-wide, no deduction; no shareholder disclosure suits or SEC cases.
- Related parties
- In the 2026 proxy the board affirmed that directors have no conflicts of interest; no material related-party transactions.
How the score works · checked as of Sep 2026
Gilead Sciences (GILD) earnings: FAQ
How does Gilead Sciences make money?
Gilead Sciences brought in $7.80 billion of revenue in Q2 2026, up 10.2% year over year. The largest source was HIV: $5.69 billion, or 73% of the total, followed by Liver Disease ($877M, 11%) and Oncology ($873M, 11%); other lines add the remaining 5%.
When is GILD's next earnings date?
Gilead Sciences (GILD) has not confirmed the date yet; Oct 29, 2026 is an estimate based on its past reporting schedule.
What time does GILD report earnings?
Gilead Sciences usually reports after market close: its latest results release was filed with the SEC at 4:03 pm ET on Aug 4, 2026.
When did GILD last report earnings?
Gilead Sciences reported Q2 2026 results on Aug 4, 2026.
What is the EPS estimate for GILD's next earnings?
The consensus EPS forecast is $2.15 (6 analysts), vs $2.47 in the same quarter last year.
Where can I find Gilead Sciences's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to GILD's filings; this page breaks the latest report down in a Sankey chart.
Does Gilead Sciences pay dividends?
Yes. In 2025, Gilead Sciences paid $4,003M in dividends on its common stock, per its 10-K. Earlier years are in the five-year table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 08/26/2026. How we make the breakdowns · Report an error
More reports: HCA · Q2 2026 · ISRG · Q2 2026 · JNJ · Q2 2026 · LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · PFE · Q2 2026 · REGN · Q2 2026 · SYK · Q2 2026 · all reports